extract: 2025-05-01-nejm-semaglutide-mash-phase3-liver

Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>

domains/health/Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md

@@ -27,6 +27,12 @@ This is not an American problem alone. The American diet and lifestyle are sprea
 
 The four major risk factors behind the highest burden of noncommunicable disease -- tobacco use, harmful use of alcohol, unhealthy diets, and physical inactivity -- are all lifestyle factors that simple interventions could address. The gap between what science knows works (lifestyle modification) and what the system delivers (pharmaceutical symptom management) represents one of the largest misalignments in the modern economy.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+GLP-1s may function as a pharmacological counter to engineered food addiction. The population-level obesity decline (39.9% to 37.0%) coinciding with 12.4% adult GLP-1 adoption suggests pharmaceutical intervention can partially offset the metabolic consequences of engineered hyperpalatable foods, though this addresses symptoms rather than root causes of the food environment.
+
 ---
 
 Relevant Notes:

domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -23,6 +23,18 @@ The competitive dynamics (Lilly vs. Novo vs. generics post-2031) will drive pric
 
 Real-world persistence data from 125,474 commercially insured patients shows the chronic use model fails not because patients choose indefinite use, but because most cannot sustain it: only 32.3% of non-diabetic obesity patients remain on GLP-1s at one year, dropping to approximately 15% at two years. This creates a paradox for payer economics—the "inflationary chronic use" concern assumes sustained adherence, but the actual problem is insufficient persistence. Under capitation, payers pay for 12 months of therapy ($2,940 at $245/month) for patients who discontinue and regain weight, capturing net cost with no downstream savings from avoided complications. The economics only work if adherence is sustained AND the payer captures downstream benefits—with 85% discontinuing by two years, the downstream cardiovascular and metabolic savings that justify the cost never materialize for most patients.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+The Cell Press review characterizes GLP-1s as marking a 'system-level redefinition' of cardiometabolic management with 'ripple effects across healthcare costs, insurance models, food systems, long-term population health.' Obesity costs the US $400B+ annually, providing context for the scale of potential cost impact. The WHO issued conditional recommendations within 2 years of widespread adoption (December 2025), unusually fast for a major therapeutic category.
+
+
+### Additional Evidence (extend)
+*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15*
+
+MASH indication adds a third organ-protection pathway (liver, after cardiovascular and kidney), strengthening the multi-indication economic case. However, the Value in Health Medicare study showed only $28M MASH savings—surprisingly small given the 63% clinical resolution rate, likely because MASH progression to transplant takes decades, placing most savings beyond the 10-year budget window.
+
 ---
 
 Relevant Notes:

domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

@@ -30,6 +30,12 @@ For value-based care models and capitated payers, this multi-organ protection cr
 - Nature Medicine: additive benefits with SGLT2 inhibitors
 - First GLP-1 to receive FDA indication for CKD in T2D patients
 
+
+### Additional Evidence (extend)
+*Source: [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] | Added: 2026-03-15*
+
+NEJM Phase 3 trial adds liver protection as a third major organ system. Semaglutide achieved 62.9% MASH resolution vs 34.3% placebo, with meta-analysis showing reduced risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients. Some hepatoprotective effects operate independently of weight loss, suggesting direct GLP-1 receptor-mediated liver benefits.
+
 ---
 
 Relevant Notes:

domains/health/the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md

@@ -31,6 +31,12 @@ Since specialization and value form an autocatalytic feedback loop where each am
 
 The Commonwealth Fund's 2024 international comparison demonstrates this transition empirically across 10 developed nations. All countries compared (Australia, Canada, France, Germany, Netherlands, New Zealand, Sweden, Switzerland, UK, US) have eliminated material scarcity in healthcare — all possess advanced clinical capabilities and universal or near-universal access infrastructure. Yet health outcomes vary dramatically. The US spends >16% of GDP (highest by far) with worst outcomes, while top performers (Australia, Netherlands) spend the lowest percentage of GDP. The differentiator is not clinical capability (US ranks 2nd in care process quality) but access structures and equity — social determinants. This proves that among developed nations with sufficient material resources, social disadvantage (who gets care, discrimination, equity barriers) drives outcomes more powerfully than clinical quality or spending volume.
 
+
+### Additional Evidence (extend)
+*Source: [[2025-06-01-cell-med-glp1-societal-implications-obesity]] | Added: 2026-03-15*
+
+GLP-1 access inequality demonstrates the epidemiological transition in action: the intervention addresses metabolic disease (post-transition health problem) but access stratifies by wealth and insurance status (social disadvantage), potentially widening health inequalities even as population-level outcomes improve. The WHO's emphasis on 'multisectoral action' and 'healthier environments' acknowledges that pharmaceutical solutions alone cannot address socially-determined health outcomes.
+
 ---
 
 Relevant Notes:

entities/internet-finance/futardio.md

@@ -49,6 +49,7 @@ MetaDAO's token launch platform. Implements "unruggable ICOs" — permissionless
 - **2026-03-05** — [[insert-coin-labs-futardio-fundraise]] launched for Web3 gaming studio (failed, $2,508 / $50K = 5% of target)
 - **2026-03-05** — [[git3-futardio-fundraise]] failed: Git3 raised $28,266 of $100K target (28.3%) before entering refunding status, demonstrating market filtering even with live MVP
 - **2024-06-14** — [[futardio-fund-rug-bounty-program]] passed: Approved $5K USDC funding for RugBounty.xyz platform development to incentivize community recovery from rug pulls
+- **2024-08-28** — MetaDAO proposal to develop futardio as memecoin launchpad with futarchy governance failed. Proposal would have allocated $100k grant over 6 months to development team. Key features: percentage of each new token supply allocated to futarchy DAO, points-to-token conversion within 180 days, revenue distribution to $FUTA holders, immutable deployment on IPFS/Arweave. Proposal rejected by market, suggesting reputational risks outweighed adoption benefits.
 ## Competitive Position
 - **Unique mechanism**: Only launch platform with futarchy-governed accountability and treasury return guarantees
 - **vs pump.fun**: pump.fun is memecoin launch (zero accountability, pure speculation). Futardio is ownership coin launch (futarchy governance, treasury enforcement). Different categories despite both being "launch platforms."

inbox/archive/.extraction-debug/2025-05-01-nejm-semaglutide-mash-phase3-liver.json

@@ -0,0 +1,24 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 1,
+    "kept": 0,
+    "fixed": 1,
+    "rejected": 1,
+    "fixes_applied": [
+      "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "glp-1-agonists-resolve-steatohepatitis-in-63-percent-of-mash-patients-through-mechanisms-partially-independent-of-weight-loss.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/.extraction-debug/2025-06-01-cell-med-glp1-societal-implications-obesity.json

@@ -0,0 +1,32 @@
+{
+  "rejected_claims": [
+    {
+      "filename": "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    },
+    {
+      "filename": "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md",
+      "issues": [
+        "missing_attribution_extractor"
+      ]
+    }
+  ],
+  "validation_stats": {
+    "total": 2,
+    "kept": 0,
+    "fixed": 2,
+    "rejected": 2,
+    "fixes_applied": [
+      "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:set_created:2026-03-15",
+      "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:set_created:2026-03-15"
+    ],
+    "rejections": [
+      "glp-1-adoption-produced-first-measurable-population-level-obesity-decline-demonstrating-pharmaceutical-intervention-can-shift-population-health-outcomes.md:missing_attribution_extractor",
+      "glp-1-access-inequality-risks-creating-two-tier-metabolic-health-system-where-pharmacological-prevention-stratifies-by-wealth-while-root-causes-remain-unaddressed.md:missing_attribution_extractor"
+    ]
+  },
+  "model": "anthropic/claude-sonnet-4.5",
+  "date": "2026-03-15"
+}

inbox/archive/2025-04-22-futardio-proposal-testing-v03-transfer.md

@@ -6,9 +6,12 @@ url: "https://www.futard.io/proposal/2dvNKyxKzVuUMcd89wzfuYjX2RKbJps2Srqu4mJ7LEg
 date: 2025-04-22
 domain: internet-finance
 format: data
-status: unprocessed
+status: enrichment
 tags: [futardio, metadao, futarchy, solana, governance]
 event_type: proposal
+processed_by: rio
+processed_date: 2026-03-15
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Proposal Details
@@ -48,3 +51,14 @@ This would be the test example for transferring the MetaDAO treasury of USDC to
 - Autocrat version: 0.3
 - Completed: 2025-04-22
 - Ended: 2025-04-22
+
+
+## Key Facts
+- Test DAO proposal 'Testing v0.3 Transfer' passed on 2025-04-22
+- Proposal aimed to transfer MetaDAO treasury USDC to v0.4 DAO
+- Proposal account: 2dvNKyxKzVuUMcd89wzfuYjX2RKbJps2Srqu4mJ7LEgC
+- Proposal number: 1
+- DAO account: GCSGFCRfCRQDbqtPLa6bV7DCJz26NkejR182or8PNqRw
+- Proposer: 8Cwx4yR2sFAC5Pdx2NgGHxCk1gJrtSTxJoyqVonqndhq
+- Autocrat version: 0.3
+- Proposal completed and ended: 2025-04-22

inbox/archive/2025-05-01-nejm-semaglutide-mash-phase3-liver.md

@@ -7,9 +7,13 @@ date: 2025-05-01
 domain: health
 secondary_domains: []
 format: paper
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, semaglutide, MASH, NASH, liver-disease, organ-protection]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -39,3 +43,10 @@ Phase 3 trial of semaglutide 2.4mg in patients with MASH and moderate or advance
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Third organ-protection pathway (after CV and kidney) strengthens the case that GLP-1s should be evaluated as multi-organ protective agents, not just weight loss drugs
 EXTRACTION HINT: The multi-organ protection thesis may justify reframing the existing GLP-1 claim from a weight-loss-economics frame to a metabolic-disease-prevention frame
+
+
+## Key Facts
+- Resmetirom (Rezdiffra) was approved for MASH in March 2024
+- MASH is projected to become the leading cause of liver transplantation
+- GLP-1 RAs reduce liver fat deposition, improve hepatocellular ballooning, and reduce lobular inflammation per 2025 meta-analysis
+- Meta-analysis shows GLP-1 RAs associated with reduced risk of major CV events, clinically significant portal hypertension, and all-cause mortality in MASLD/MASH patients

inbox/archive/2025-06-01-cell-med-glp1-societal-implications-obesity.md

@@ -7,9 +7,13 @@ date: 2025-06-01
 domain: health
 secondary_domains: [entertainment, internet-finance]
 format: paper
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, obesity, societal-impact, equity, food-systems, population-health, sustainability]
+processed_by: vida
+processed_date: 2026-03-15
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated.md", "the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -52,3 +56,11 @@ EXTRACTION HINT: Focus on both the population-level effect AND the equity concer
 
 flagged_for_clay: ["GLP-1 adoption is reshaping cultural narratives around obesity, body image, and pharmaceutical solutions to behavioral problems — connects to health narrative infrastructure"]
 flagged_for_rio: ["GLP-1 equity gap creates investment opportunity in access-focused models that serve underserved populations — potential Living Capital thesis"]
+
+
+## Key Facts
+- October 2025 Gallup poll: 12.4% of US adults taking GLP-1 for weight loss (30M+ people)
+- US obesity prevalence: 39.9% (2022) → 37.0% (2025), representing 7.6M fewer obese Americans
+- WHO issued conditional recommendations for GLP-1s in December 2025
+- Obesity costs US $400B+ annually
+- WHO three-pillar approach: healthier environments (population policy), protect high-risk individuals, person-centered care